| Primary |
| Aspergillosis |
25.9% |
| Prophylaxis |
9.3% |
| Pneumonia |
8.1% |
| Bronchopulmonary Aspergillosis |
7.7% |
| Fungal Infection |
7.7% |
| Antifungal Prophylaxis |
4.9% |
| Chemotherapy |
4.8% |
| Antibiotic Therapy |
4.2% |
| Immunosuppression |
3.2% |
| Pyrexia |
3.0% |
| Pain |
2.7% |
| Infection |
2.7% |
| Cough |
2.6% |
| Immunosuppressant Drug Therapy |
2.3% |
| Infection Prophylaxis |
2.3% |
| Systemic Candida |
1.8% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Febrile Neutropenia |
1.7% |
| Supplementation Therapy |
1.7% |
| Dyspepsia |
1.6% |
|
| Death |
16.3% |
| Renal Failure Acute |
9.6% |
| Septic Shock |
8.8% |
| Photosensitivity Reaction |
7.2% |
| Pneumonia |
6.3% |
| Sepsis |
5.5% |
| Vision Blurred |
5.2% |
| Squamous Cell Carcinoma |
4.7% |
| Drug Interaction |
3.9% |
| Nervous System Disorder |
3.9% |
| Visual Impairment |
3.6% |
| Zygomycosis |
3.6% |
| Respiratory Failure |
3.3% |
| Drug Ineffective |
3.0% |
| Drug Resistance |
3.0% |
| Periostitis |
2.8% |
| Drug Level Increased |
2.5% |
| No Adverse Event |
2.5% |
| Hy's Law Case |
2.2% |
| Neuromyopathy |
2.2% |
|
| Secondary |
| Aspergillosis |
16.9% |
| Product Used For Unknown Indication |
16.2% |
| Bronchopulmonary Aspergillosis |
10.4% |
| Prophylaxis |
6.8% |
| Antifungal Prophylaxis |
5.0% |
| Pyrexia |
4.4% |
| Pneumonia |
4.0% |
| Acute Lymphocytic Leukaemia |
3.9% |
| Acute Myeloid Leukaemia |
3.6% |
| Systemic Candida |
3.5% |
| Immunosuppression |
3.1% |
| Pain |
3.1% |
| Drug Use For Unknown Indication |
3.1% |
| Aspergillus Infection |
3.0% |
| Chemotherapy |
2.9% |
| Fungal Infection |
2.3% |
| Immunosuppressant Drug Therapy |
2.3% |
| Infection |
2.2% |
| Infection Prophylaxis |
1.8% |
| Diabetes Mellitus |
1.6% |
|
| Septic Shock |
12.4% |
| Respiratory Failure |
11.1% |
| Venoocclusive Liver Disease |
8.4% |
| Renal Failure Acute |
7.5% |
| Nephropathy Toxic |
6.8% |
| Death |
6.6% |
| Squamous Cell Carcinoma |
4.8% |
| Bronchopulmonary Aspergillosis |
4.5% |
| Vomiting |
4.5% |
| Drug Ineffective |
4.0% |
| Drug Resistance |
3.5% |
| Encephalopathy |
3.5% |
| Pneumonia |
3.5% |
| Zygomycosis |
3.1% |
| Pyrexia |
3.0% |
| Sepsis |
3.0% |
| Venoocclusive Disease |
3.0% |
| Bradycardia |
2.5% |
| Systemic Mycosis |
2.3% |
| Hy's Law Case |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.5% |
| Prophylaxis |
11.4% |
| Drug Use For Unknown Indication |
9.4% |
| Infection Prophylaxis |
8.2% |
| Acute Myeloid Leukaemia |
6.0% |
| Bone Marrow Conditioning Regimen |
4.5% |
| Prophylaxis Against Graft Versus Host Disease |
4.1% |
| Acute Lymphocytic Leukaemia |
4.0% |
| Antifungal Prophylaxis |
3.7% |
| Premedication |
3.0% |
| Aplastic Anaemia |
2.2% |
| Fungal Infection |
2.0% |
| Supportive Care |
1.9% |
| Antiviral Prophylaxis |
1.8% |
| Aspergillosis |
1.8% |
| Pain |
1.7% |
| Bronchopulmonary Aspergillosis |
1.5% |
| Pyrexia |
1.4% |
| Pneumonia |
1.4% |
| Graft Versus Host Disease |
1.4% |
|
| Drug Ineffective |
11.9% |
| Pyrexia |
8.9% |
| White Blood Cell Count Decreased |
7.9% |
| Multi-organ Failure |
7.5% |
| Pneumonia |
6.8% |
| Sepsis |
6.4% |
| Septic Shock |
5.7% |
| Thrombocytopenia |
5.5% |
| Vomiting |
5.4% |
| Respiratory Failure |
4.7% |
| Febrile Neutropenia |
3.9% |
| Death |
3.6% |
| Renal Failure Acute |
3.6% |
| Renal Failure |
3.2% |
| Infection |
3.0% |
| Tumour Lysis Syndrome |
2.8% |
| Graft Versus Host Disease |
2.5% |
| Rash |
2.4% |
| Systemic Mycosis |
2.2% |
| Tachycardia |
2.2% |
|
| Interacting |
| Antifungal Prophylaxis |
12.6% |
| Fungal Infection |
10.6% |
| Bronchopulmonary Aspergillosis |
6.8% |
| Product Used For Unknown Indication |
6.1% |
| Hiv Infection |
5.9% |
| Prophylaxis Against Graft Versus Host Disease |
5.4% |
| Aspergillosis |
5.2% |
| Prophylaxis |
4.7% |
| Transplant |
4.7% |
| Immunosuppressant Drug Therapy |
4.5% |
| Acute Myeloid Leukaemia |
4.3% |
| Immunosuppression |
4.1% |
| Graft Versus Host Disease |
3.8% |
| Aspergillus Infection |
3.6% |
| Infection Prophylaxis |
3.6% |
| Febrile Neutropenia |
3.2% |
| Liver Transplant |
3.2% |
| Drug Use For Unknown Indication |
2.7% |
| Stem Cell Transplant |
2.7% |
| Alternaria Infection |
2.3% |
|
| Drug Interaction |
20.0% |
| Idiopathic Pneumonia Syndrome |
8.0% |
| Rhabdomyolysis |
7.2% |
| Pulmonary Alveolar Haemorrhage |
6.4% |
| Stomatitis |
6.4% |
| Vomiting |
6.4% |
| Extrasystoles |
4.0% |
| Hepatic Enzyme Increased |
4.0% |
| Photosensitivity Reaction |
4.0% |
| Renal Impairment |
4.0% |
| Torsade De Pointes |
4.0% |
| Drug Level Increased |
3.2% |
| Immunosuppressant Drug Level Increased |
3.2% |
| Nervous System Disorder |
3.2% |
| Potentiating Drug Interaction |
3.2% |
| Toxicity To Various Agents |
3.2% |
| Feeling Abnormal |
2.4% |
| Hallucination |
2.4% |
| Neurotoxicity |
2.4% |
| Neutropenia |
2.4% |
|
